SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 15th, 2005 • Viragen Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 15, 2005 among Viragen, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 15th, 2005 • Viragen Inc • Biological products, (no disgnostic substances)
This Registration Rights Agreement (this “Agreement”) is made and entered into as of September ___, 2005, among Viragen, Inc., a Delaware corporation (the “Company”), and the purchasers signatory hereto (each such purchaser is a “Purchaser” and collectively, the “Purchasers”).
COMMON STOCK PURCHASE WARRANT To Purchase __________ Shares of Common Stock of VIRAGEN, INC.Viragen Inc • September 15th, 2005 • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___(the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the third year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Viragen, Inc., a Delaware corporation (the “Company”), up to ___shares (the “Warrant Shares”) of Common Stock, par value $0.01 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
AMORTIZING CONVERTIBLE DEBENTUREViragen Inc • September 15th, 2005 • Biological products, (no disgnostic substances) • New York
THIS AMORTIZING CONVERTIBLE DEBENTURE is one of a series of duly authorized and issued Amortizing Convertible Debentures of Viragen, Inc., a Delaware corporation, having a principal place of business at (the “Company”), designated as its Amortizing Convertible Debenture (this debenture, the “Debenture” and collectively with the other such series of debentures, the “Debentures”).
AMENDMENT AGREEMENTAmendment Agreement • September 15th, 2005 • Viragen Inc • Biological products, (no disgnostic substances)
AGREEMENT dated effective September 15, 2005, by and between Viragen, Inc. (“Viragen”), a Delaware corporation (“Viragen”) and ___(“Purchaser”). Capitalized terms used in this Agreement and not otherwise defined herein shall have the respective meanings accorded to them in that certain Purchase Agreement dated April 1, 2004 by and between Viragen and Purchaser (the “Purchase Agreement”).
